Peptides Similar to Davunetide
Compare Davunetide with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Cerebrolysin: Moderate - Both are neuroprotective peptides studied for neurodegenerative disease
- •Semax: Moderate - Both are intranasal neuroprotective peptides
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Davunetide (current) | - | - |
| Cerebrolysin | Moderate - Both are neuroprotective peptides studied for neurodegenerative disease | Davunetide is a defined octapeptide targeting microtubules via intranasal delivery, while cerebrolysin is a mixture of neurotrophic peptides administered intravenously with broader mechanisms. |
| Semax | Moderate - Both are intranasal neuroprotective peptides | Davunetide stabilizes microtubules while semax modulates BDNF and neurotransmitter pathways. Semax is approved in Russia. |
| Pinealon | Low-Moderate - Both are short neuroprotective peptides | Davunetide is an octapeptide microtubule stabilizer, while pinealon is a tripeptide that modulates gene expression in brain tissue. |
CerebrolysinModerate - Both are neuroprotective peptides studied for neurodegenerative disease
Differences
Davunetide is a defined octapeptide targeting microtubules via intranasal delivery, while cerebrolysin is a mixture of neurotrophic peptides administered intravenously with broader mechanisms.
Advantages
Defined single compound, intranasal delivery, approved in several countries for stroke and TBI
Disadvantages
Requires IV administration, undefined mixture, less specific mechanism
SemaxModerate - Both are intranasal neuroprotective peptides
Differences
Davunetide stabilizes microtubules while semax modulates BDNF and neurotransmitter pathways. Semax is approved in Russia.
Advantages
Clinical approval in Russia, well-characterized nootropic effects, decades of use
Disadvantages
Different mechanism (neurotransmitter vs microtubule), no tauopathy data
PinealonLow-Moderate - Both are short neuroprotective peptides
Differences
Davunetide is an octapeptide microtubule stabilizer, while pinealon is a tripeptide that modulates gene expression in brain tissue.
Advantages
Very small size (tripeptide), oral bioavailability
Disadvantages
Less clinical evidence, unclear mechanism, no clinical trials
Peptides Related to Davunetide#
Davunetide is distinguished by its specific microtubule-stabilizing mechanism and its derivation from the ADNP protein. The following comparisons examine neuroprotective peptides with related clinical applications.
Cerebrolysin#
Cerebrolysin is a mixture of neurotrophic peptides derived from porcine brain. Unlike davunetide's defined structure and specific microtubule target, cerebrolysin contains multiple active components with broader neuroprotective mechanisms. Cerebrolysin requires IV administration but has more clinical evidence and regulatory approvals.
Semax#
Both davunetide and semax are administered intranasally for CNS applications. However, their mechanisms differ fundamentally: davunetide stabilizes microtubules while semax acts through BDNF and neurotransmitter modulation. Semax has clinical approval in Russia for cognitive enhancement and stroke recovery.
Pinealon#
Pinealon is a synthetic tripeptide with neuroprotective properties in preclinical studies. Both peptides target neuronal survival but through different mechanisms. Davunetide has substantially more clinical evidence from the PSP trial.
Summary Comparison#
| Feature | Davunetide | Cerebrolysin | Semax | Pinealon |
|---|---|---|---|---|
| Mechanism | Microtubule stabilization | Neurotrophic mixture | BDNF/neurotransmitter | Gene expression |
| Route | Intranasal | IV | Intranasal | Oral/intranasal |
| Clinical status | Discontinued (PSP); Phase 3 (ADNP) | Approved (multiple) | Approved (Russia) | Preclinical |
| Size | 8 amino acids | Mixture | 7 amino acids | 3 amino acids |
Comparison Context#
Davunetide belongs to the Neuroprotective category of research peptides. Comparing Davunetide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Davunetide in mechanism, indication, or therapeutic category:
Davunetide vs Cerebrolysin#
Similarity: Moderate - Both are neuroprotective peptides studied for neurodegenerative disease
Key Differences: Davunetide is a defined octapeptide targeting microtubules via intranasal delivery, while cerebrolysin is a mixture of neurotrophic peptides administered intravenously with broader mechanisms.
Advantages of Cerebrolysin: Defined single compound, intranasal delivery, approved in several countries for stroke and TBI
Disadvantages of Cerebrolysin: Requires IV administration, undefined mixture, less specific mechanism
Researchers choosing between Davunetide and Cerebrolysin should consider the development stage, available evidence, and specific research objectives when making their selection.
Davunetide vs Semax#
Similarity: Moderate - Both are intranasal neuroprotective peptides
Key Differences: Davunetide stabilizes microtubules while semax modulates BDNF and neurotransmitter pathways. Semax is approved in Russia.
Advantages of Semax: Clinical approval in Russia, well-characterized nootropic effects, decades of use
Disadvantages of Semax: Different mechanism (neurotransmitter vs microtubule), no tauopathy data
Researchers choosing between Davunetide and Semax should consider the development stage, available evidence, and specific research objectives when making their selection.
Davunetide vs Pinealon#
Similarity: Low-Moderate - Both are short neuroprotective peptides
Key Differences: Davunetide is an octapeptide microtubule stabilizer, while pinealon is a tripeptide that modulates gene expression in brain tissue.
Advantages of Pinealon: Very small size (tripeptide), oral bioavailability
Disadvantages of Pinealon: Less clinical evidence, unclear mechanism, no clinical trials
Researchers choosing between Davunetide and Pinealon should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Davunetide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer